Section Image

Interactive Panel Discussion

"The Future Of Biotech: Managing Clinical Trials In The Internet Economy"

TUESDAY, JUNE 18, 2002

Dr. C. Budd Colby, Principal, Colby Biomedical Consultants
Bob Andreatta, Chief Financial Officer and Chief Operating Officer, Hopelink Corporation
Mr. Thomas Tremblay, Director of Clinical Operations, POINT Biomedical Corporation (

Moderator: Dr. Naomi Fried, General Manager and Vice President for Business Development, 1747, Inc. (

Click here to view the Summary for this Interactive Panel Discussion.
(Adobe Acrobat Reader is needed to view the documents above).

Registration and Networking: 5:00 - 6:00 p.m.
Panel: 6:00 - 8:00 p.m.
Open to the Public. $20 fee. No fee to Center Sponsors.
Pre-registration highly recommended due to limited seating.

The rapid pace of new drug development, the plethora of biotech companies in need of getting drugs to the market, and the advent of the Internet and Web are having a strong impact on the structuring and management of clinical trials -- the expensive and time-consuming process of testing medical drugs that occur in three overlapping phases which last several years each. The right strategic business decisions and compliance with the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) are key to the success of clinical trials, inevitably getting new drugs to the U.S. market.

At this Panel, come hear experts in the biotech industry put their stake on the ground on the following questions:

Will the processing and management of clinical trials be 'Web-ified'? If so, in what time horizon?
What mediating technology and non-technology factors are needed for clinical trials to incorporate Internet- and Web-based solutions?
What challenges are biotech companies facing in structuring and managing clinical trials? For instance, in the areas of patient acquisition and case management; data acquisition, storage, retrieval, and mining; and data analysis?
What solutions, including Internet- and Web-based ones, exist to meet these challenges?
What critical technology solutions are still needed?

Come hear about these developments during the first half of this two-hour Panel. During the second hour, audience participants will have the opportunity to engage in a lively, interactive discussion with the panelists.

C. Budd Colby is Principal at Colby Biomedical Consultants, an international private consulting practice providing services to diverse members of the biotechnology industry community. Dr. Colby has 12 years of academic research experience in the areas of biochemistry, genetics, virology, and cell biology with emphasis on their application to cancer and infectious diseases.

Beginning in 1967, Dr. Colby held research and teaching positions at a number of prestigious academic institutions and carried out research in the areas of cancer and infectious diseases. In 1979, Dr. Colby initiated and managed the recombinant interferon program at Cetus Corporation where he established and coordinated international research and business. In 1983, he joined Triton Biosciences, Inc. as the Founding Scientist and Senior Director of Technology Development. From 1992-1995, he served as Vice President, Research & Development at Metabolex, Inc., a biotechnology company focused on diabetes. Between 1998-2001, he held the positions of Vice President, Business Development and Chief Operating Officer of Neugenesis Corporation. At Sloan Kettering Institute, Dr. Colby was Research Associate and Founding Member of the International Laboratories for the Molecular Biology of Interferon Systems. Dr. Colby earned his B.S. in Chemistry at Memphis State University and his Ph.D. in Biochemistry at the University of Kentucky.

Bob Andreatta is Chief Financial Officer & Chief Operating Officer at HopeLink Corporation ( He brings over 17 years of experience in growth management and planning for complex financial, technical accounting, and regulatory environments in both private and public companies. Mr. Andreatta was most recently a Partner in KPMG's technology practice in the San Francisco Bay Area where he specialized in software, media, and service companies, including many successful startups. He oversaw numerous IPOs and transaction work; supported companies in the development of their business plans, systems, policies, and complex transactions; and led consulting and international assignments. In 1995, he took leadership of KPMG's Internet and Start-Up Practices in San Francisco. Mr. Andreatta was a member of KPMG's National E-Commerce Strategy Leadership Team and Silicon Valley Marketing Council and headed the company's New Media Practice on the West Coast. He is a graduate of Santa Clara University with a B.S. in Business.

Naomi Fried is General Manager and Vice President for Business Development at 1747, Inc. ( Dr. Fried has over 12 years of experience in engineering and healthcare. During the past four years, she has assisted eHealth start-ups in fundraising, developing business strategies and strategic partnerships, and creating Web-based revenue models. Former clients have included medical content Web sites, vertical health portals, alternative health networks, and risk and disease management providers. Dr. Fried advised Stanford’s School of Medicine in the creation and spin-out of its medical informatics Internet start-up e-SKOLAR (formerly SHINE), as well as served as Interim President during its first year. Dr. Fried earned a B.S. in Chemistry from the University of California at Berkeley (summa cum laude) and a Ph.D. in Materials Science Engineering from MIT.

Nandini Tandon is Partner in the Life Sciences team at RBC Capital Partners (, the venture capital arm of RBC Financial Group.  She joined the team in early 2002, opening their San Francisco offices.  Dr.Tandon has extensive experience in business development with Chiron Corporation, Hyseq, Inc., and Zyomyx, Inc.  She has also worked at Bay BioTech Link, a consulting firm, as well as Glaxo, Inc., the UK-headquartered pharmaceutical company.  Dr. Tandon holds a Ph.D. in biochemistry from Duke University and a B.S. in chemistry from Hollins College.

Thomas Tremblay is Director of Clinical Operations at POINT Biomedical Corporation (, responsible for implementing the clinical development plan for CARDIOsphere™, an ultrasound contrast agent being developed for the diagnosis of coronary artery disease and myocardial perfusion defects. Mr. Tremblay is a registered nurse and has worked in various clinical settings from outpatient clinics to intensive care units. For the past 12 years, Mr. Tremblay has worked in clinical research beginning as a Study Coordinator at the University of California in San Francisco and, more recently, as a Clinical Research Associate and Project Manager at Genentech; Clinical Operations Manager at Titan Pharmaceuticals; and Assistant Director of Clinical Operations at IntraBiotics Pharmaceuticals, Inc.

Registration is not necessary, but highly recommended due to limited seating. To register, send your name, title, company name, telephone number, and email address to:

Ms. Claire Kahrobaie
Manager, Client Services
Silicon Valley World Internet Center
T: 650.462.9800